Xolair (omalizumab) has been around since the early 2000s as a treatment for severe allergic asthma, but found a new lease of life in 2014 when it was approved for CSU, with sales reaching $1.4 ...

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...